# PharmaEssentia

Source: https://onco.cc/companies/pharmaessentia/  
OnCo record `pharmaessentia` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PharmaEssentia is a Taiwanese biotechnology company whose long-acting interferon ropeginterferon alfa-2b (Besremi) is approved for polycythaemia vera, a chronic blood cancer, in the United States, Europe and Asia.

## Summary

PharmaEssentia, based in Taipei and listed on the Taipei Exchange, developed ropeginterferon alfa-2b, a mono-pegylated interferon given every two weeks, as a disease-modifying treatment for polycythaemia vera and other myeloproliferative neoplasms. Marketed as Besremi, it was approved in the European Union in 2019 through its partner AOP Health and by the FDA in November 2021, the first interferon approved for the condition in the United States, and is in phase 3 trials for essential thrombocythaemia. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: PharmaEssentia Corporation; 藥華醫藥
- Tags: ctgov-sponsor
- HQ: Taipei
- Type: biotech
- Website: https://www.pharmaessentia.com

## Sources

- Official website: https://www.pharmaessentia.com
- ClinicalTrials.gov: trials led by PharmaEssentia: https://clinicaltrials.gov/search?lead=PharmaEssentia
- Wikipedia: https://en.wikipedia.org/wiki/PharmaEssentia

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET](https://onco.cc/trials/nct05482971/), [A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU](https://onco.cc/trials/nct05485948/), [A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV](https://onco.cc/trials/nct05481151/), [Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients](https://onco.cc/trials/nct04655092/), [P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk](https://onco.cc/trials/nct06468033/), [PROUD-PV and CONTINUATION-PV](https://onco.cc/trials/proud-pv/), [Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance](https://onco.cc/trials/nct04285086/)

---
JSON: https://onco.cc/api/v1/entities/pharmaessentia.json